The role of acetylation of histone H3 and H4 in oral squamous cell carcinoma-Reference-Cited by-全球学者库

The role of acetylation of histone H3 and H4 in oral squamous cell carcinoma

Published:2023-03-01 Issue:2 Volume:25 Page:111-118
ISSN:1765-2839
Container-title:Oncologie
language:en
Short-container-title:

Author:

Li Lian¹²,Tang Donge¹²,Dai Yong²

Affiliation:

1. College of Life Science , Guangxi Normal University , Guilin , Guangxi , China

2. Clinical Medical Research Center, Guangdong Provincial Engineering Research Center of Autoimmune Disease Precision Medicine, Shenzhen Engineering Research Center of Autoimmune Disease , The Second Clinical Medical College of Jinan University (Shenzhen People’s Hospital) , Shenzhen , Guangdong , China

Abstract

Abstract Oral squamous cell carcinoma (OSCC), which commonly develops in the tongue, buccal mucosa, and epithelium of the oral cavity, is the result of an accumulation of genetic and epigenetic alterations. In OSCC, other epigenetic alterations, such as histone modification were present. Histone modification can predict the prognosis of various cancers. Actually, the regulation and remodeling of chromatin structure caused by histone acetylation was crucial for the growth of tumors. Histone acetylation has received extensive research in OSCC, particularly histone H3 and H4. Additionally, the bulk of OSCC treatment plans focused on controlling the degree of histone acetylation. The acetylation sites of histone H3 and H4 that evolved in OSCC and the effects of these modifications on histone are therefore summarized below. Furthermore, the treatment of OSCC was implemented from the realization of normalizing histone acetylation levels in OSCC, and we summarized target drugs in the resumption of OSCC acetylation level. This review could help with understanding and treating OSCC.

Funder

Guangxi Key Laboratory of Metabolic Diseases Research

Shenzhen Key Medical Discipline Construction Fund

Publisher

Walter de Gruyter GmbH

Subject

Oncology

Link

https://www.degruyter.com/document/doi/10.1515/oncologie-2023-0071/pdf

Reference72 articles.

1. Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. https://doi.org/10.3322/caac.21660.

2. Chai, AWY, Lim, KP, Cheong, SC. Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol 2020;61:71–83. https://doi.org/10.1016/j.semcancer.2019.09.011.

3. Chen, C, Lohavanichbutr, P, Zhang, Y, Houck, JR, Upton, MP, Abedi-Ardekani, B, et al.. Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: a multicenter study using FFPE samples. Oral Oncol 2020;100:104487. https://doi.org/10.1016/j.oraloncology.2019.104487.

4. Chai, AWY, Yee, PS, Price, S, Yee, SM, Lee, HM, Tiong, VK, et al.. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. Elife 2020;9:e57761. https://doi.org/10.7554/elife.57761.

5. Li, CC, Shen, Z, Bavarian, R, Yang, F, Bhattacharya, A. Oral cancer: genetics and the role of precision medicine. Dent Clin 2018;62:29–46. https://doi.org/10.1016/j.cden.2017.08.002.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. POTENTIAL OF MELATONIN TO REVERSE EPIGENETIC ABERRATIONS IN ORAL CANCER: NEW FINDINGS;EXCLI J;2023